--- title: CDMO Daily News — August 20, 2026 slug: daily-news-2026-08-20-cdmo site: cdmo post_kind: news byline: BioBM description: August 20 CDMO daily: SK pharmteco Opens Small-Molecule and HPAPI Manufacturing Expansions in Ireland; Cytovance Biologics Launches Standalone Analytical… canonical_url: https://www.cdmo.directory/posts/daily-news-2026-08-20-cdmo published_at: 2026-08-20T00:00:43.738Z last_updated: 2026-08-20T00:02:38.796Z --- ### [SK pharmteco](/companies/skpharmteco) Opens Small-Molecule and HPAPI Manufacturing Expansions in Ireland - [SK pharmteco](/companies/skpharmteco) completed two GMP facilities at its Swords, Ireland campus: a multi-purpose small-molecule API facility with 26.5 m³ reactor capacity (three 8,000 L reactors) and a kilo-scale HPAPI/ADC payload facility supporting batch sizes up to 1.5 kg. - The HPAPI facility handles ultra-high-potency compounds with occupational exposure limits as low as 10 ng/m³, featuring isolators, high-pressure chromatography, and lyophilization to bridge clinical and commercial GMP production. **Operational Impact** [SK pharmteco](/companies/skpharmteco)'s Swords expansions add 26.5 m³ of small-molecule reactor capacity and dedicated kilo-scale HPAPI/ADC manufacturing, reducing clinical-to-commercial transition risk for potent-compound programs in Europe. *Source: [Contract Pharma Breaking News RSS](https://www.contractpharma.com/breaking-news/sk-pharmteco-completes-facility-expansions-in-swords-ireland)* --- ### [Cytovance Biologics](/companies/cytovance-biologics) Launches Standalone Analytical Services for Biologics Development - [Cytovance Biologics](/companies/cytovance-biologics) now offers analytical services independently of manufacturing engagements, covering method development, validation, characterization, release testing, and stability studies. - Services span early-stage through commercial programs under both GMP and non-GMP environments, targeting sponsors with limited internal lab capacity. **Operational Impact** Cytovance's standalone analytical model reduces switching costs for sponsors evaluating manufacturing partners, allowing them to validate analytical readiness before committing to manufacturing capacity. *Source: [PharmaSource RSS](https://pharmasource.global/content/news/cdmo-news/cytovance-biologics-expands-standalone-analytical-services-for-biologics)* --- ### [Andelyn Biosciences](/companies/andelynbio) to Manufacture AAV9-GM2 Gene Therapy for Queen's University - [Andelyn Biosciences](/companies/andelynbio), a cell and gene therapy CDMO, will develop and manufacture AAV9-GM2, a gene therapy candidate for GM2 gangliosidoses including Tay-Sachs and Sandhoff diseases. - Andelyn will deploy its AAV Curator Platform to execute a multi-phase manufacturing program to support clinical dosing of the therapy. **Operational Impact** Andelyn expands its AAV gene therapy manufacturing footprint by adding a multi-phase GM2 program, demonstrating continued capacity deployment in rare-disease viral-vector manufacturing. *Source: [Contract Pharma Breaking News RSS](https://www.contractpharma.com/breaking-news/andelyn-biosciences-partners-with-queens-university-on-gm2-gene-therapy)* --- ### Piramal Pharma Increases [Yapan Bio](/companies/yapan-bio) Stake to 74% for $7.95M, Bolsters ADC Platform - Piramal Pharma acquired an additional 40.67% stake in Hyderabad-based CDMO [Yapan Bio](/companies/yapan-bio) for ₹76 crore ($7.95M), raising total ownership to 74% and making it a subsidiary. - Integration expands [Piramal Pharma Solutions](/companies/piramalpharmasolutions)' large-molecule capabilities and strengthens its ADCelerate platform for antibody-drug conjugate development from Phase I through GMP in 12 months. **Operational Impact** [Piramal Pharma Solutions](/companies/piramalpharmasolutions) gains integrated large-molecule and ADC manufacturing capacity in India, enabling its ADCelerate platform to compress Phase I-to-GMP timelines to 12 months and address rising demand for complex biologics outsourcing. *Source: [PharmaSource RSS](https://pharmasource.global/content/news/cdmo-news/piramal-pharma-acquires-40-67-stake-in-yapan-bio-for-7-95m)* --- ### Genprex Partners with U.S. CDMO for AAV Diabetes Gene Therapy Scale-Up - Genprex signed a development and manufacturing agreement with an unnamed U.S. CDMO to scale cGMP production of its AAV-based diabetes gene therapy. - The partnership covers process optimization, bioreactor scale-up, analytical development, and drug product supply for IND-enabling studies and clinical trials. - Manufacturing activities target improved production efficiency, increased dose availability for multicenter trials, and regulatory-compliant potency and stability assurance. **Operational Impact** The unnamed CDMO gains AAV gene-therapy manufacturing volume for a Phase-1-stage diabetes program requiring multicenter trial capacity and commercial-scale bioreactor infrastructure. *Source: [PharmaSource RSS](https://pharmasource.global/content/news/cdmo-news/genprex-selects-u-s-cdmo-to-scale-diabetes-gene-therapy-manufacturing)* ## References 1. [Contract Pharma Breaking News RSS — SK pharmteco Opens Small-Molecule and HPAPI Manufacturing Expansions in Ireland](https://www.contractpharma.com/breaking-news/sk-pharmteco-completes-facility-expansions-in-swords-ireland) 2. [PharmaSource RSS — Cytovance Biologics Launches Standalone Analytical Services for Biologics Development](https://pharmasource.global/content/news/cdmo-news/cytovance-biologics-expands-standalone-analytical-services-for-biologics) 3. [Contract Pharma Breaking News RSS — Andelyn Biosciences to Manufacture AAV9-GM2 Gene Therapy for Queen's University](https://www.contractpharma.com/breaking-news/andelyn-biosciences-partners-with-queens-university-on-gm2-gene-therapy) 4. [PharmaSource RSS — Piramal Pharma Increases Yapan Bio Stake to 74% for $7.95M, Bolsters ADC Platform](https://pharmasource.global/content/news/cdmo-news/piramal-pharma-acquires-40-67-stake-in-yapan-bio-for-7-95m) 5. [PharmaSource RSS — Genprex Partners with U.S. CDMO for AAV Diabetes Gene Therapy Scale-Up](https://pharmasource.global/content/news/cdmo-news/genprex-selects-u-s-cdmo-to-scale-diabetes-gene-therapy-manufacturing) Source: https://www.cdmo.directory/posts/daily-news-2026-08-20-cdmo